Coya Therapeutics (NASDAQ:COYA – Get Free Report) and Evogene (NASDAQ:EVGN – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.
Earnings and Valuation
This table compares Coya Therapeutics and Evogene”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Coya Therapeutics | $4.69 million | 16.36 | -$21.23 million | ($1.39) | -2.35 |
| Evogene | $1.66 million | 1.90 | -$8.48 million | ($0.91) | -0.40 |
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Coya Therapeutics and Evogene, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Coya Therapeutics | 1 | 0 | 5 | 0 | 2.67 |
| Evogene | 1 | 0 | 0 | 0 | 1.00 |
Coya Therapeutics presently has a consensus target price of $15.00, indicating a potential upside of 358.72%. Given Coya Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Coya Therapeutics is more favorable than Evogene.
Profitability
This table compares Coya Therapeutics and Evogene’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Coya Therapeutics | -643.44% | -66.91% | -60.13% |
| Evogene | -694.18% | -156.53% | -86.80% |
Volatility & Risk
Coya Therapeutics has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Comparatively, Evogene has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500.
Institutional and Insider Ownership
39.8% of Coya Therapeutics shares are owned by institutional investors. Comparatively, 10.4% of Evogene shares are owned by institutional investors. 6.1% of Coya Therapeutics shares are owned by company insiders. Comparatively, 7.4% of Evogene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Coya Therapeutics beats Evogene on 9 of the 14 factors compared between the two stocks.
About Coya Therapeutics
Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies that enhance the function of regulatory T cells, or Tregs. Tregs help regulate immune activity, and the company is studying their potential to address neurodegenerative diseases and other conditions involving inflammation and immune dysfunction. The company’s lead investigational program, COYA 101, is an autologous Treg cell therapy being evaluated for amyotrophic lateral sclerosis (ALS). The treatment is designed to use a patient’s own regulatory T cells, which are expanded and functionally enhanced outside the body before being administered.
About Evogene
Evogene Ltd. (NASDAQ: EVGN) is an Israel-based computational biology company that develops technologies and products designed to improve human health, agriculture and sustainability. The company uses artificial intelligence, machine learning and biological data analysis through its Computational Predictive Biology platform to identify and develop solutions based on biological mechanisms. Evogene has built a portfolio of subsidiaries and business units focused on areas including agricultural biologicals, crop protection, microbiome-based therapeutics and medical cannabis.
Receive News & Ratings for Coya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
